Japanese pharmaceutical company Eisai, together with Oita University in Japan, has built what could be the world's first AI model that uses data from wearable devices to predict Alzheimer's disease, the most common form of dementia.
Their research team embarked on a study to create a cost-effective, practical tool to pre-screen people suspected of developing the disease. Their findings were...
Japanese pharmaceutical company Eisai has established a new digital health business targeting dementia.
WHY IT MATTERS
Eisai's newly formed wholly-owned subsidiary, Theoria Technologies Co., seeks to "accelerate the development of a dementia ecosystem." This ecosystem, according to a press release, will empower people with dementia to "live their fullest lives."
Commencing business in April 2024...
A digital brain assessment tool by ASX-listed neuroscience tech company Cogstate is coming to Taiwan and Hong Kong.
On Thursday, the Cogstate announced that CogMate, the global multilingual version of its NouKNOW digital tool for self-assessment of brain performance, will be distributed by pharmaceutical firm Eisai in the two Asian markets.
WHAT IT DOES
Accessible via web and mobile devices,...
Unlearn, a startup creating digital twins used in the control arm of clinical trials, announced today an extension to its Series A funding round, bringing the total amount raised to $15 million.
New investors Eisai, Epic Ventures and Alumni Ventures Group contributed to the oversubscribed round. They join 8VC, DCVC, DCVC Bio and Mubadala Capital Ventures, which contributed to Unlearn’s original...
